Novel Combretastatin A-4 Analogs-Design, Synthesis, and Antiproliferative and Anti-Tubulin Activity.
Marta JędrzejczykBenedetta MorabitoBarbara Żyżyńska-GranicaMarta StrugaJan JanczakMaral AminpourJack Adam TuszynskiAdam HuczyńskiPublished in: Molecules (Basel, Switzerland) (2024)
Combretastatins isolated from the Combretum caffrum tree belong to a group of closely related stilbenes. They are colchicine binding site inhibitors which disrupt the polymerization process of microtubules in tubulins, causing mitotic arrest. In vitro and in vivo studies have proven that some combretastatins exhibit antitumor properties, and among them, combretastatin A-4 is the most active mitotic inhibitor. In this study, a series of novel combretastatin A-4 analogs containing carboxylic acid, ester, and amide moieties were synthesized and their cytotoxic activity against six tumor cell lines was determined using sulforhodamine B assay. For the most cytotoxic compounds ( 8 and 20 ), further studies were performed. These compounds were shown to induce G0/G1 cell cycle arrest in MDA and A549 cells, in a concentration-dependent manner. Moreover, in vitro tubulin polymerization assays showed that both compounds are tubulin polymerization enhancers. Additionally, computational analysis of the binding modes and binding energies of the compounds with respect to the key human tubulin isotypes was performed. We have obtained a satisfactory correlation of the binding energies with the IC 50 values when weighted averages of the binding energies accounting for the abundance of tubulin isotypes in specific cancer cell lines were computed.
Keyphrases
- cell cycle arrest
- cell death
- pi k akt
- cell cycle
- density functional theory
- dna binding
- endothelial cells
- high throughput
- magnetic resonance
- molecular docking
- induced apoptosis
- papillary thyroid
- signaling pathway
- squamous cell carcinoma
- oxidative stress
- case control
- magnetic resonance imaging
- cell proliferation
- breast cancer cells
- lymph node metastasis
- drug induced
- pluripotent stem cells